Here are some practical steps to consider: Monitor Retinal Health : Ensure that patients on GLP-1 medications receive regular eye exams, particularly if they have a history of diabetic retinopathy

Taking the Next Step with Rixa Health Our Medical Weightloss Approach for PCOS cuts through the noise and confusion with a clear, science-backed protocol: Initial Consultation and Assessment Your journey begins with a comprehensive evaluation: Detailed medical history focusing on your PCOS symptoms Review of previous treatments and their effectiveness Discussion of your specific goals beyond weight loss Explanation of how GLP-1 medications work specifically for your PCOS type Answering all your questions (no rushing through appointments) Your Personalized Treatment Plan Based on your assessment, we create a tailored plan that includes: The optimal GLP-1 medication and starting dose for your specific needs A PCOS-specific nutrition approach that works with the medication Supplement recommendations to address common PCOS deficiencies Activity guidance optimized for hormone balance Clear expectations and timeline for results Ongoing Support and Optimization Your progress is carefully monitored with: Regular check-ins to assess symptoms, side effects, and results Dose adjustments based on your response Lab work to track hormonal improvements, not just weight Modifications to your plan as needed to maximize results Educational resources to help you understand your body Ready to finally address the root cause of your PCOS rather than just managing symptoms

Semaglutide GLP-1 may not be appropriate for everyone, especially those with a history of severe gastrointestinal problems, active pancreatitis, certain thyroid cancers, multiple endocrine neoplasia syndrome type 2, severe eating disorders, or a history of medullary thyroid carcinoma in ones family or personal
Hu, Y., Bhupathiraju, S
Within 100 days, MAHA will provide an assessment on the state of that crisis across several factors including disease in America vs
12 , , (-4,1%)